{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:52:58Z","timestamp":1791377578536,"version":"4.3.2"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund Guangdong-Hong Kong-Macau Joint Lab","award":["MY2022KF01"],"award-info":[{"award-number":["MY2022KF01"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372691"],"award-info":[{"award-number":["82372691"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Natural Science Research Grant","award":["2023A1515010324"],"award-info":[{"award-number":["2023A1515010324"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2024B1515020029"],"award-info":[{"award-number":["2024B1515020029"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-026-02144-7","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:25:00Z","timestamp":1778595900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of METTL3 and PRMT5 as an oncogenic pair for the prognosis and therapeutic targets of colorectal cancer subtype"],"prefix":"10.1186","volume":"18","author":[{"given":"Qian","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrui","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2144_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.canlet.2021.09.034","volume":"522","author":"N Li","year":"2021","unstructured":"Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255\u201368.","journal-title":"Cancer Lett"},{"issue":"23","key":"2144_CR2","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389(23):2125\u201339.","journal-title":"N Engl J Med"},{"issue":"3","key":"2144_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S, Zitnjak D, Krogh M, Petersen LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412\u201320.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2144_CR4","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.7150\/ijbs.82361","volume":"20","author":"ZJ Huang","year":"2024","unstructured":"Huang ZJ, Li YJ, Yang J, Huang L, Zhao Q, Lu YF, et al. PTPLAD1 Regulates PHB-Raf Interaction to Orchestrate Epithelial-Mesenchymal and Mitofusion-Fission Transitions in Colorectal Cancer. Int J Biol Sci. 2024;20(6):2202\u201318.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"2144_CR5","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jpha.2023.06.005","volume":"13","author":"XL Liang","year":"2023","unstructured":"Liang XL, Ouyang L, Yu NN, Sun ZH, Gui ZK, Niu YL, et al. Histone deacetylase inhibitor pracinostat suppresses colorectal cancer by inducing CDK5-Drp1 signaling-mediated peripheral mitofission. J Pharm Anal. 2023;13(10):1168\u201382.","journal-title":"J Pharm Anal"},{"issue":"1","key":"2144_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.","journal-title":"Mol Cancer"},{"issue":"1","key":"2144_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-019-1038-7","volume":"18","author":"T Li","year":"2019","unstructured":"Li T, Hu P-S, Zuo Z, Lin J-F, Li X, Wu Q-N, et al. METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18(1):112.","journal-title":"Mol Cancer"},{"issue":"6","key":"2144_CR8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen M, Wei L, Law CT, Tsang FHC, Shen J, Cheng CLH, et al. RNA N6-methyladenosine methyltransferase\u2010like 3 promotes liver cancer progression through YTHDF2\u2010dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67(6):2254\u201370.","journal-title":"Hepatology"},{"issue":"7544","key":"2144_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature14281","volume":"519","author":"CR Alarc\u00f3n","year":"2015","unstructured":"Alarc\u00f3n CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. N6-methyladenosine marks primary microRNAs for processing. Nature. 2015;519(7544):482\u20135.","journal-title":"Nature"},{"key":"2144_CR10","doi-asserted-by":"crossref","unstructured":"Zha X, Xi X, Fan X, Ma M, Zhang Y, Yang Y. Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3pPTENAkt signaling cascade through DGCR8. (2020).","DOI":"10.18632\/aging.103130"},{"issue":"8","key":"2144_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41556-022-00968-y","volume":"24","author":"X Wei","year":"2022","unstructured":"Wei X, Huo Y, Pi J, Gao Y, Rao S, He M, et al. METTL3 preferentially enhances non-m6A translation of epigenetic factors and promotes tumourigenesis. Nat Cell Biol. 2022;24(8):1278\u201390.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2144_CR12","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1038\/s41467-021-23501-5","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, Shao F, Yang X, Wang J, Zhu R, Yang Y, et al. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nat Commun. 2021;12(1):3803.","journal-title":"Nat Commun"},{"issue":"4","key":"2144_CR13","doi-asserted-by":"publisher","first-page":"115484","DOI":"10.1016\/j.celrep.2025.115484","volume":"44","author":"Q Xia","year":"2025","unstructured":"Xia Q, Zhong R, Zheng J, Zhou X, Zhao X, Wang S et al. PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms. Cell Rep. 2025; 44(4): 115484.","journal-title":"Cell Rep"},{"key":"2144_CR14","doi-asserted-by":"crossref","unstructured":"Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R et al. m 6 A RNA methyltransferases METTL3\/14 regulate immune responses to anti-PD\u20101 therapy. EMBO J. 2020;39(20).","DOI":"10.15252\/embj.2020104514"},{"issue":"12","key":"2144_CR15","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","volume":"20","author":"A Lex","year":"2014","unstructured":"Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: Visualization of Intersecting Sets. IEEE Trans Vis Comput Graph. 2014;20(12):1983\u201392.","journal-title":"IEEE Trans Vis Comput Graph"},{"issue":"6","key":"2144_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41589-022-00984-x","volume":"18","author":"K Toshimitsu","year":"2022","unstructured":"Toshimitsu K, Takano A, Fujii M, Togasaki K, Matano M, Takahashi S, et al. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. Nat Chem Biol. 2022;18(6):605\u201314.","journal-title":"Nat Chem Biol"},{"key":"2144_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1073\/pnas.2518675122","volume":"122","author":"Y Wang","year":"2025","unstructured":"Wang Y, Huang ZJ, Yu NN, Liang JZ, Zeng YH, Zhao Q, Zhou YP, Zeng YJ, Sun ZH, Zhang S, He QY, Zhang J. MLKL\/retromer axis controls PD-L1 recycling to compromise antitumor immunity during VCP inhibition-induced necroptosis. Proc Natl Acad Sci U S A. 2025;122:51.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2144_CR18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.ymthe.2023.05.015","volume":"31","author":"Y Wang","year":"2023","unstructured":"Wang Y, Chen YY, Gao GB, Zheng YH, Yu NN, Ouyang L, Gao X, Li N, Wen SY, Huang S, Zhao Q, Liu L, Cao M, Zhang S, Zhang J, He QY. Polyphyllin D punctures hypertrophic lysosomes to reverse drug resistance of hepatocellular carcinoma by targeting acid sphingomyelinase. Mol Ther. 2023;31(7):2169\u201387.","journal-title":"Mol Ther"},{"key":"2144_CR19","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"5","key":"2144_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411\u201320.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2144_CR21","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1111\/jcmm.15063","volume":"24","author":"H Xie","year":"2020","unstructured":"Xie H, Li J, Ying Y, Yan H, Jin K, Ma X, et al. METTL3\/YTHDF2 m6A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. J Cell Mol Med. 2020;24(7):4092\u2013104.","journal-title":"J Cell Mol Med"},{"key":"2144_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2019.07.015","volume":"66","author":"DP Panigrahi","year":"2020","unstructured":"Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Patra S, Behera BP, et al. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. Semin Cancer Biol. 2020;66:45\u201358.","journal-title":"Semin Cancer Biol"},{"key":"2144_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.omtn.2019.11.022","volume":"19","author":"W Zhao","year":"2020","unstructured":"Zhao W, Qi X, Liu L, Ma S, Liu J, Wu J. Epigenetic Regulation of m(6)A Modifications in Human Cancer. Mol Ther Nucleic Acids. 2020;19:405\u201312.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"2144_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","volume":"163","author":"H Chen","year":"2022","unstructured":"Chen H, Pan Y, Zhou Q, Liang C, Wong CC, Zhou Y, et al. METTL3 Inhibits Antitumor Immunity by Targeting m(6)A-BHLHE41-CXCL1\/CXCR2 Axis to Promote Colorectal Cancer. Gastroenterology. 2022;163(4):891\u2013907.","journal-title":"Gastroenterology"},{"issue":"1","key":"2144_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-019-1038-7","volume":"18","author":"T Li","year":"2019","unstructured":"Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, et al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18(1):112.","journal-title":"Mol Cancer"},{"issue":"1","key":"2144_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18(1):110.","journal-title":"Mol Cancer"},{"issue":"7","key":"2144_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/gutjnl-2019-319639","volume":"69","author":"Q Wang","year":"2020","unstructured":"Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, et al. METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69(7):1193\u2013205.","journal-title":"Gut"},{"key":"2144_CR28","doi-asserted-by":"publisher","first-page":"6149558","DOI":"10.1155\/2021\/6149558","volume":"2021","author":"Y Ai","year":"2021","unstructured":"Ai Y, Liu S, Luo H, Wu S, Wei H, Tang Z, et al. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1. J Immunol Res. 2021;2021:6149558.","journal-title":"J Immunol Res"},{"issue":"18","key":"2144_CR29","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1182\/bloodadvances.2021006306","volume":"6","author":"M Rethnam","year":"2022","unstructured":"Rethnam M, Tan DQ, Tan SH, Li J, Yokomori R, Li Y, et al. Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling. Blood Adv. 2022;6(18):5330\u201344.","journal-title":"Blood Adv"},{"issue":"10","key":"2144_CR30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jpha.2023.06.005","volume":"13","author":"XL Liang","year":"2023","unstructured":"Liang XL, Ouyang L, Yu NN, Sun ZH, Gui ZK, Niu YL, He QY, Zhang J, Wang Y. Histone deacetylase inhibitor pracinostat suppresses colorectal cancer by inducing CDK5-Drp1 signaling-mediated peripheral mitofission. J Pharm Anal. 2023;13(10):1168\u201382.","journal-title":"J Pharm Anal"},{"issue":"22","key":"2144_CR31","doi-asserted-by":"publisher","first-page":"e2101672","DOI":"10.1002\/advs.202101672","volume":"8","author":"Y Xie","year":"2021","unstructured":"Xie Y, Xie F, Zhang L, Zhou X, Huang J, Wang F, et al. Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells. Adv Sci (Weinh). 2021;8(22):e2101672.","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"2144_CR32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.chembiol.2023.09.001","volume":"31","author":"H Yu","year":"2024","unstructured":"Yu H, Liu J, Bu X, Ma Z, Yao Y, Li J, et al. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy. Cell Chem Biol. 2024;31(4):776\u2013e917.","journal-title":"Cell Chem Biol"},{"issue":"3","key":"2144_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/genes14030678","volume":"14","author":"Y Abe","year":"2023","unstructured":"Abe Y, Sano T, Tanaka N. The Role of PRMT5 in Immuno-Oncology. Genes (Basel). 2023;14(3):678.","journal-title":"Genes (Basel)"},{"issue":"21","key":"2144_CR34","doi-asserted-by":"publisher","first-page":"9429","DOI":"10.1021\/acs.jmedchem.8b00598","volume":"61","author":"Y Wang","year":"2018","unstructured":"Wang Y, Hu W, Yuan Y. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery. J Med Chem. 2018;61(21):9429\u201341.","journal-title":"J Med Chem"},{"key":"2144_CR35","doi-asserted-by":"publisher","first-page":"e13964","DOI":"10.7554\/eLife.13964","volume":"5","author":"Z Mounir","year":"2016","unstructured":"Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M et al. 2016 ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. Elife 5: e13964.","journal-title":"Elife"},{"issue":"6","key":"2144_CR36","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-13-0884","volume":"74","author":"F Yan","year":"2014","unstructured":"Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res. 2014;74(6):1752\u201365.","journal-title":"Cancer Res"},{"key":"2144_CR37","doi-asserted-by":"publisher","first-page":"112368","DOI":"10.1016\/j.biopha.2021.112368","volume":"145","author":"W Abumustafa","year":"2022","unstructured":"Abumustafa W, Zamer BA, Khalil BA, Hamad M, Maghazachi AA, Muhammad JS. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies. Biomed Pharmacother. 2022;145:112368.","journal-title":"Biomed Pharmacother"},{"issue":"7860","key":"2144_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597\u2013601.","journal-title":"Nature"},{"issue":"6","key":"2144_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jpha.2023.04.009","volume":"13","author":"H Xiao","year":"2023","unstructured":"Xiao H, Zhao R, Meng W, Liao Y. Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer. J Pharm Anal. 2023;13(6):625\u201339.","journal-title":"J Pharm Anal"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02144-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02144-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02144-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:44:08Z","timestamp":1786333448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02144-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2144"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02144-7","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Consent for this study was obtained from the review Board of the Ethics Committee of Jinan University (JNUKY-2023-0092) and the Ethics Committee of Shanghai Outdo Biotechnology Company (YB M-05-02).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"151"}}